Bristol Myers Squibb

Official Name: Bristol-Myers Squibb Company

Headquarters: New York, NY, United States

Founded: 1887

Employees: 32,200

CEO: Dr. Giovanni Caforio M.D.

show_chart NYSE: BMY +0.44%

Market Cap

$130.84 Billion

USD as of July 1, 2023

history Market Cap History

Company Description

Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

Bristol Myers Squibb market capitalization evolution

Evolution of Bristol-Myers Squibb Company market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Bristol-Myers Squibb Company

Detailed Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Stocks & Indices

Bristol-Myers Squibb Company has the following listings and related stock indices.

Stock: NYSE: BMY

Stock: FSX: BRM

Stock: XETR: BRM

Key People

Founder(s): William Mc Laren Bristol John Ripley Myers E. R. Squibb

Giovanni Caforio, M. D. (Chairman & CEO) David Elkins (CFO)


Revenue: US$42.518 billion (2020)

Operating income: US$30.745 billion (2020)

Net income: US$8.995 billion (2020)

Total assets: US$129.44 billion (2019)

Total equity: US$59.70 billion (2019)



430 East 29th Street

14th Floor

New York, NY 10016

United States

Phone: 212 546 4000